Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis (Q33867316)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

title

Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

1 reference

Gail D Lewis Phillips

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Merry C Nishimura

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Jennifer Arca Lacap

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Samir Kharbanda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Elaine Mai

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Janet Tien

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Kimberly Malesky

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Simon P Williams

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Jan Marik

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Heidi S Phillips

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

10 May 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

581-591

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

20 March 2020

copyright license

start time

10 May 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Activity of T-DM1 in Her2-positive breast cancer brain metastases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Emerging strategies for treating brain metastases from breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

CNS metastases in breast cancer: old challenge, new frontiers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Trastuzumab emtansine for HER2-positive advanced breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Brain metastases as preventive and therapeutic targets

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Quality of life in brain metastases radiation trials: a literature review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Trastuzumab--mechanism of action and use in clinical practice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Targeted therapy for brain metastases: improving the therapeutic ratio

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Magnetic resonance imaging in experimental models of brain disorders

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5495871

Treating recurrent cases of squamous cell carcinoma with radiotherapy

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-017-4279-4

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28493046

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28493046

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10549-017-4279-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

20 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28493046%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

28493046

1 reference